Filtered By:
Cancer: Lymphoma

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 33102 results found since Jan 2013.

MALT lymphoma prognostic index
Source: Blood - September 21, 2017 Category: Hematology Tags: Free Research Articles, CME article CONTINUING MEDICAL EDUCATION (CME) QUESTIONS Source Type: research

Genomic analysis of adult Burkitt lymphoma
Source: Blood - October 19, 2017 Category: Hematology Tags: Free Research Articles, CME article CONTINUING MEDICAL EDUCATION (CME) QUESTIONS Source Type: research

Diffuse large B-cell lymphoma in the elderly
Source: Blood - November 16, 2017 Category: Hematology Tags: Free Research Articles, CME article CONTINUING MEDICAL EDUCATION (CME) QUESTIONS Source Type: research

How to Diagnose and Treat Breast Implant–Associated Anaplastic Large Cell Lymphoma
Learning Objectives: After reading this article, the participant should be able to: 1. Describe the diagnostic criteria for breast implant–associated (BIA) anaplastic large cell lymphoma (ALCL). 2. Appropriately evaluate a patient with suspected BIA-ALCL, including appropriate imaging, laboratory tests, and pathologic evaluation. 3. Understand the operative treatment of BIA-ALCL, and indications for systemic chemotherapy and/or radiation therapy in advanced disease. 4. Understand treatment outcomes and prognosis based on stage of disease. Summary: The goal of this continuing medical education module is to present th...
Source: Plastic and Reconstructive Surgery - March 30, 2018 Category: Cosmetic Surgery Tags: CME Source Type: research

Human oncoviruses: Mucocutaneous manifestations, pathogenesis, therapeutics, and prevention
In 1964, the first human oncovirus, Epstein –Barr virus, was identified in Burkitt lymphoma cells. Since then, 6 other human oncoviruses have been identified: human papillomavirus, Merkel cell polyomavirus, hepatitis B and C viruses, human T-cell lymphotropic virus-1, and human herpesvirus-8. These viruses are causally linked to 12% of all cancers, many of which have mucocutaneous manifestations. In addition, oncoviruses are associated with multiple benign mucocutaneous diseases. Research regarding the pathogenic mechanisms of oncoviruses and virus-specific treatment and prevention is rapidly evolving.
Source: Journal of the American Academy of Dermatology - November 27, 2018 Category: Dermatology Authors: Christopher T. Haley, Uyen Ngoc Mui, Ramya Vangipuram, Peter L. Rady, Stephen K. Tyring Tags: Continuing medical education Source Type: research

The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Pathways and targets for immune restoration and tumor eradication
Cutaneous T cell lymphomas (CTCLs) are malignancies of skin-trafficking T cells. Patients with advanced CTCL manifest immune dysfunction that predisposes to infection and suppresses the antitumor immune response. Therapies that stimulate immunity have produced superior progression-free survival compared with conventional chemotherapy, reinforcing the importance of addressing the immune deficient state in the care of patients with CTCL. Recent research has better defined the pathogenesis of these immune deficits, explaining the mechanisms of disease progression and revealing potential therapeutic targets.
Source: Journal of the American Academy of Dermatology - December 18, 2020 Category: Dermatology Authors: Joseph S. Durgin, David M. Weiner, Maria Wysocka, Alain H. Rook Tags: Continuing medical education Source Type: research

The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Current and future approaches
In the past few decades, immunotherapy has emerged as an effective therapeutic option for patients with cutaneous T cell lymphoma (CTCL). CTCL is characterized by progressive impairment of multiple arms of the immune system. Immunotherapy targets these deficits to stimulate a more robust antitumor response, thereby both clearing the malignant T cells and repairing the immune dysfunction. By potentiating rather than suppressing the immune system, immunotherapy can result in longer treatment responses than alternatives such as chemotherapy.
Source: Journal of the American Academy of Dermatology - December 18, 2020 Category: Dermatology Authors: David M. Weiner, Joseph S. Durgin, Maria Wysocka, Alain H. Rook Tags: Continuing medical education Source Type: research

This Month in JAAD: March 2021
In this issue of the JAAD, two continuing medical education manuscripts address the pathogenesis of cutaneous T-cell lymphoma and emerging information about therapeutic targets. Kartan et  al (page 615) performed a retrospective cross-sectional review of patients with cutaneous T-cell lymphoma treated with topical corticosteroid monotherapy and report a 73% response rate. They remind us that topical steroid monotherapy may be an effective option, especially in patients with early-st age disease. Greenberg et al (page 639) report retrospective data on the prevalence of comorbidities with palmoplantar psoriasis.
Source: Journal of the American Academy of Dermatology - February 16, 2021 Category: Dermatology Authors: Dirk Elston Tags: This month in Source Type: research

The role of radiation therapy in the management of cutaneous malignancies. Part II: When is radiation therapy indicated?
Radiation therapy may be performed for a variety of cutaneous malignancies depending on patient health status, tumor clinical and histologic features, patient preference, and resource availability. Dermatologists should be able to recognize the clinical scenarios in which radiation therapy is appropriate as this may reduce morbidity, decrease risk of disease recurrence, and improve quality of life. The second article in this 2-part continuing medical education series focuses on the most common indications for radiation therapy in the treatment of basal cell carcinoma, cutaneous squamous cell carcinoma, dermatofibrosarcoma ...
Source: Journal of the American Academy of Dermatology - June 8, 2021 Category: Dermatology Authors: Kelly M. Wilmas, Wesley B. Garner, Matthew T. Ballo, Susan L. McGovern, Deborah F. MacFarlane Source Type: research

Primary cutaneous T-cell lymphomas other than mycosis fungoides and S ézary syndrome. Part II: Prognosis and management
Primary cutaneous T-cell lymphomas (CTCLs) other than mycosis fungoides (MF) and S ézary syndrome (SS) encompass a heterogenous group of non-Hodgkin lymphomas with variable clinical courses, prognoses, and management approaches. Given the morphologic and histologic overlap among the CTCL subtypes and other T-cell lymphomas with cutaneous manifestations, thorough evaluation with c linicopathologic correlation and exclusion of systemic involvement are essential prior to initiating therapy.Staging and treatment recommendations vary, depending on the subtype, clinical behavior, and treatment response.
Source: Journal of the American Academy of Dermatology - April 30, 2021 Category: Dermatology Authors: Yuna Oh, Joseph R. Stoll, Alison Moskowitz, Melissa Pulitzer, Steven Horwitz, Patricia Myskowski, Sarah J. Noor Tags: Continuing medical education Source Type: research

Primary cutaneous T-cell lymphomas other than mycosis fungoides and S ézary syndrome. Part I: Clinical and histologic features and diagnosis
Primary cutaneous T-cell lymphomas (CTCLs) are defined as lymphomas with a T-cell phenotype that present in the skin without evidence of systemic or extracutaneous disease at initial presentation. CTCLs other than mycosis fungoides and S ézary syndrome (SS) account for approximately one third of CTCLs and encompass a heterogenous group of non-Hodgkin lymphomas, ranging from indolent lymphoproliferative disorders to aggressive malignancies with a poor prognosis. The spectrum of CTCLs continues to broaden as new provisional entities are classified.
Source: Journal of the American Academy of Dermatology - April 30, 2021 Category: Dermatology Authors: Joseph R. Stoll, Jonathan Willner, Yuna Oh, Melissa Pulitzer, Alison Moskowitz, Steven Horwitz, Patricia Myskowski, Sarah J. Noor Tags: Continuing medical education Source Type: research

Racial/Ethnic Health Disparities in Dermatology in the United States Part 2: Disease-specific Epidemiology, Characteristics, Management, and Outcomes
Racial and ethnic disparities in dermatology negatively affect outcomes such as mortality and quality of life. Dermatologists and dermatologic surgeons should be familiar with disease-specific inequities that may influence their practice. The second article in this two-part continuing medical education series highlights gaps in frequency, clinical presentation, management, and outcomes by race and ethnicity. We review cutaneous malignancies including basal cell carcinoma, squamous cell carcinoma, melanoma, Merkel cell carcinoma, dermatofibrosarcoma protuberans, and cutaneous T cell lymphoma, and inflammatory disorders incl...
Source: Journal of the American Academy of Dermatology - February 6, 2022 Category: Dermatology Authors: Kimberly Shao, Jette Hooper, Hao Feng Source Type: research

Variations in genetics, biology, and phenotype of cutaneous disorders in skin of color – Part I: Genetic, biologic, and structural differences in skin of color
Skin of color (SOC) populations include those who identify as Black/African, Hispanic/Latinx, Asian/Pacific Islander, American Indian/Native Alaskan, Indigenous Australian, Middle Eastern, biracial/multiracial, or non-White; this list is far from exhaustive and may vary between and within cultures. Recent genetic and immunological studies have suggested that cutaneous inflammatory disorders (atopic dermatitis, psoriasis, and hidradenitis suppurativa) and malignancies (melanoma, basal cell carcinoma, and cutaneous T-cell lymphoma) may have variations in their immunophenotype among SOC.
Source: Journal of the American Academy of Dermatology - July 6, 2022 Category: Dermatology Authors: Jessica B. Brown-Korsah, Shanice McKenzie, Deega Omar, Nicole C. Syder, Nada Elbuluk, Susan C. Taylor Tags: Continuing medical education Source Type: research

An update on Epstein-Barr virus –and human T-lymphotropic virus type-1–induced cutaneous manifestations. CME Part II
The Epstein-Barr virus (EBV) is a DNA virus that infects 90% of the human population, is responsible for certain cutaneous lymphomas (extranodal NK/T-cell lymhoma, hydroa vacciniforme lymphoproliferative disorder, lymphomatoid granulomatosis, others), and can be associated with a variety of cutaneous manifestations (eg, infectious mononucleosis, severe mosquito bite allergy, chronic active EBV disease, Gianotti-Crosti syndrome). EBV-related skin disorders are frequent in certain populations (South and Cental America, Africa, Asia, and Oceania) and can be diagnostically challenging.
Source: Journal of the American Academy of Dermatology - August 29, 2022 Category: Dermatology Authors: Alejandro A. Gru, Jose A. Plaza, Jose A. Sanches, Denis Miyashiro, Omar P. Sangueza, Francisco Bravo Puccio, Sonia Toussaint, J. Martin Sangueza Tags: Continuing medical education Source Type: research